A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels

Abstract EN

Noninvasive fibrosis tests are highly needed but have not been well studied in chronic hepatitis B patients with normal or minimally elevated alanine aminotransferase (ALT) levels.

This study is aimed at developing a noninvasive score system to predict liver fibrosis in these patients.

HBeAg-positive chronic hepatitis B patients with ALT levels of <80 IU/l and liver histology (n=290) were assigned to training (n=203) or validation (n=87) groups.

Training group patients were divided into nonsignificant (F0–1) and significant fibrosis (F2–4) according to METAVIR stages.

Logistic regression was performed to identify factors for liver fibrosis and develop a score system.

The capacity of the score to identify the severity of fibrosis was displayed by receiver operating characteristic curve (ROC) and area under ROC (AUROC) values.

Multivariate logistic regression showed that HBeAg (ratios of the sample to the cutoff values (S/CO)) and liver stiffness measurement (LSM; kilopascals (kPa)) were independent factors of liver fibrosis.

A score system composed of HBeAg and LSM by assigning a point of 1, 2, or 3 to different HBeAg and LSM levels, respectively, was developed.

The scores 2-3, 4, and 5-6 of the sum of HBeAg and LSM points indicated nonsignificant, indeterminate, and significant fibrosis, respectively.

The score system had an AUROC of 0.880 and showed similar performance in validation group patients.

The accuracy for identifying significant and nonsignificant fibrosis was 77.14% in validation group patients and 71.26% in the entire group of patients.

It is suggested that this noninvasive score system can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in HBeAg-positive patients with normal or minimally elevated ALT levels.